Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01543776 · ClinicalTrials.gov registry record · Phase 2
Food Effect Study of Abiraterone Acetate for Treatment of Patients With Castration-Resistant Prostate Cancer
A Phase 2 study, sponsored by University of Chicago.
- Completed
- Registry status
- Phase 2
- Development phase
- 72
- Enrollment target
NCT01543776 is a Phase 2 study that has completed, run by University of Chicago. The registered enrollment target is 72 participants.
The verdict
NCT01543776, a Phase 2 study, has completed, sponsored by University of Chicago.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 72 participants
- Enrollment target
Study Summary
This randomized phase II trial studies the best way to give abiraterone acetate in treating patients with castration-resistant prostate cancer. Abiraterone acetate is effective in treating castrate resistant prostate cancer and is taken in the fasting state. However, the body's absorption of abiraterone is increased with food intake. This study will test the whether a lower dose of abiraterone taken with food has a similar effect on prostate specific antigen (PSA) compared to full dose taken fasting.
Interventions
- DRUG abiraterone acetate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 72 participants |
| Start Date | 2012-01 |
| Est. Completion | 2017-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01543776
The ClinicalTrials.gov registry entry for NCT01543776 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 72 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Chicago, which has 796 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which abiraterone acetate is the first listed.
NCT01543776 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01543776 about?
NCT01543776 is a clinical study titled "Food Effect Study of Abiraterone Acetate for Treatment of Patients With Castration-Resistant Prostate Cancer". This randomized phase II trial studies the best way to give abiraterone acetate in treating patients with castration-resistant prostate cancer. Abiraterone acetate is effective in treating castrate resistant prostate cancer and is taken in the fasting state. However, the body's absorption of abirate...
What is the current status of trial NCT01543776?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 72 participants. The study started on 2012-01. Estimated completion is 2017-12.
What interventions are being tested in trial NCT01543776?
The interventions under investigation include: abiraterone acetate (DRUG).
Who is sponsoring clinical trial NCT01543776?
This trial is sponsored by University of Chicago, which has 796 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.